MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 5:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will present at the H.C. Wainwright Global Life
Sciences Conference which will be available on demand starting on
March 9, 2021 at 7:00 am (ET). Interested parties can access a link
to the on demand webcast of the presentation from the Events &
Presentations section of the Company's website at
http://www.mannkindcorp.com. The webcast replay will remain
available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung
diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin
in the United States, where it is available by prescription
from pharmacies nationwide. Afrezza is also available by
prescription in Brazil where it is commercialized by the
Company’s partner Biomm SA. MannKind is headquartered
in Westlake Village, California, and has a state-of-the-art
manufacturing facility in Danbury, Connecticut. The Company
also employs field sales and medical representatives across
the U.S. For further information, visit
www.mannkindcorp.com.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024